Cyclophilin A was revealed as a candidate marker for human oral submucous fibrosis by proteomic analysis
- 7 September 2017
- journal article
- Published by IOS Press in Cancer Biomarkers
- Vol. 20 (3), 345-356
- https://doi.org/10.3233/cbm-170142
Abstract
Oral submucous fibrosis (OSF) is a chronic insidious disease which predisposes to oral cancer. Understanding the molecular markers for OSF is critical for diagnosis and treatment of oral cancer. In this study, the proteins expression profile of OSF tissues was compared to normal mucous tissues by 2 dimensional electrophoresis (2-DE). The 2-DE images were analyzed through cut, spot detection and match analysis using mass spectrometry (MS). Differentially expressed genes were identified as candidates. RT-PCR, Western Blot and immunohistochemistry were performed to validate the difference in expression of the candidates between OSF and normal mucous tissues. The shRNA targeted to the candidates were then transfected by Lipofectamine2000 to the 3T3 cells to study gene function. Cell proliferation and apoptosis were measured by MTT, clonogenic formation, PI and TUNEL staining. From the proteomic analysis, 94 of the 182 selected spots with differential expression were identified by MS analysis and Cyclophilin A (CYPA) was determined to be the OSF-associated protein candidate. The significant differences in expression between OSF and normal tissues were verified and confirmed by RT-PCR, Western blot and Immunohistochemical analysis. Inhibition of CYPA expression by RNA interference suggested its potential activities involved in cell proliferation and apoptosis process. In conclusion, these results indicated a novel molecular mechanism of OSF pathogenesis and demonstrated CYPA as a potential biomarker and gene intervention targets of OSF. These data may help the development for therapeutics of oral cancer.Keywords
This publication has 31 references indexed in Scilit:
- Defining Salivary Biomarkers Using Mass Spectrometry-Based Proteomics: A Systematic ReviewOMICS: A Journal of Integrative Biology, 2011
- Cyclosporin A and atherosclerosis — Cellular pathways in atherogenesisPharmacology & Therapeutics, 2010
- Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of managementOral Oncology, 2009
- Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signalBiochemical and Biophysical Research Communications, 2007
- Fusion of Cyclophilin A to Fv1 Enables Cyclosporine-Sensitive Restriction of Human and Feline Immunodeficiency VirusesJournal of Virology, 2007
- Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin AJournal of Leukocyte Biology, 2007
- Mutation in the loop C-terminal to the cyclophilin A binding site of HIV-1 capsid protein disrupts proper virus assembly and infectivityRetrovirology, 2007
- Mass spectrometric proteomics profiles ofin vivo tumor secretomes: Capillary ultrafiltration sampling of regressive tumor massesProteomics, 2006
- Proteomic analysis of cancer-cell mitochondriaNature Reviews Cancer, 2003
- Presence of autoantibodies to peptidyl-prolyl cis-trans isomerase (cyclosporin A-binding protein) in systemic lupus erythematosusClinical Immunology and Immunopathology, 1992